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ABSTRACT
Objective: The objective of this study is to evaluate and compare the free radical scavenging activities of selective dopamine agonist namely ropinirole 
and pramipexole.
Methods: The antioxidant activity of ropinirole and pramipexole at various concentrations was done by 1, 1-diphenyl-2picrylhydrazyl (DPPH) free 
radical scavenging assay comparing it with ascorbic acid which was taken as standard.
Results: The free radical scavenging property as measured by DPPH method showed that ropinirole and pramipexole have got a potent free radical 
scavenging activity with that of ascorbic acid.
Conclusion: Novel drugs such as pramipexole and ropinirole are promising molecules in the field of oxidative damage related neurodegenerative 
disorders providing us an optimistic targeted approach toward neuroprotection.
Keywords: Free radical scavenging, 1, 1-diphenyl-2picrylhydrazyl assay, Anti-Parkinson’s, Dopamine agonist.
INTRODUCTION
Parkinson’s disease is a slowly progressing neurodegenerative 
disorder characterized by bradykinesia (slowing of movements), 
rigidity, increased muscle tone, tremors, and postural instability 
which is mainly due to loss or depletion of dopaminergic neurons in 
the substantia nigra [1]. The cause of this disease is multifactorial 
although the exact mechanism is still unknown. Recent studies have 
suggested that oxidative stress and abnormalities in the mitochondria 
can lead to increased free radical formation which might contribute 
to the pathogenesis of Parkinson’s disease [2]. Administration of an 
exogenous neurotoxin called MPTP is also said to cause this disease due 
to selective loss of dopaminergic neurons in substantia nigra [3]. The 
main aim of drug therapy in Parkinsonism is to provide symptomatic 
relief to the patient by use of drugs that can restore the dopaminergic 
and cholinergic balance that is disturbed in this case. Dopamine itself 
cannot be given as it cannot cross the blood-brain barrier (BBB), and 
its peripheral effects have no benefits in Parkinsonism patients. Hence, 
levodopa - the precursor of dopamine - is given, which can cross the BBB 
and get decarboxylated to dopamine on entering the brain. However, 
dopamine, which is formed from exogenously administered levodopa, is 
reported to be neurotoxic due to its conversion to some toxic products 
such as quinones and other free radicals [4,5]. These free radicals 
released might further increase the oxidative stress contributing to the 
pathogenesis of Parkinson’s disease. Moreover, patients on long-term 
levodopa therapy experience a lot of adverse effects such as “on-off” 
phenomenon, dyskinesias, wearing off phenomenon, hallucinations, 
delusions, sleep disturbances, and schizophrenia-like symptoms [6]. 
These shortcomings of levodopa lead to the need for newer therapeutic 
agents with a neuroprotective role in the treatment of Parkinson’s 
disease [7]. Now, dopamine agonists such as bromocriptine, ropinirole, 
pergolide, pramipexole, cabergoline, and rotigotine have said to have a 
neuroprotective effect in experiments conducted on animal models [8]. 
They have also reported to prevent the clinical progression of disease. 
Studies have shown that ergot derivatives of dopamine agonists such as 
bromocriptine and cabergoline have free radical scavenging property 
and possess antioxidant activity in vivo and in vitro. However, the main 
disadvantage of the ergot derivatives is increase in adverse effects such 
as anorexia, nausea, vomiting, vertigo, postural hypotension, painless 
peripheral vasospasm (spasm of digits), peripheral edema, pleural 
fibrosis, and erythromelegia [9]. These ergot derivatives also have poor 
tolerability profile. These drawbacks of ergot derivatives are overcome 
by non-ergot derivatives such as ropinirole and pramipexole which 
have fewer side effects and better tolerability profile [10]. However, 
unlike the ergot dopamine agonists, very few studies have reported 
the neuroprotective role of non-ergot derivatives of dopamine agonists 
such as ropinirole, pramipexole, and talipexole. The neuroprotective 
role of these non-ergot dopamine agonists is also probably because of 
its free radical scavenging and antioxidant activity. Hence, this study 
was undertaken to evaluate the antioxidant and free radical scavenging 
activity of non-ergot dopamine agonists - ropinirole and pramipexole, 
novel agents used in the treatment of Parkinson’s disease using the 
in vitro 1, 1-diphenyl-2picrylhydrazyl (DPPH) assay.
Objective
The objective of the present study was to evaluate and compare the 
antioxidant potential and free radical scavenging activity of ropinirole 
and pramipexole - non-ergot dopamine agonists used in the treatment 




DPPH and drugs pramipexole and ropinirole were obtained from the 
Sigma Chemical Co. CRC, Bangalore. Ascorbic acid was obtained from 
the SD Fine-Chem. Limited, Biosar, India.
DPPH free radical scavenging activity
DPPH radical scavenging activity was done using the method of 
Brand-Williams et al. (1995) [11-13]. The DPPH assay is based on the 
reduction of DPPH a stable free radical. The DPPH solution was prepared 
(0.004% w/v) in 95% ethanol. The reaction mixture containing 1 ml of 
DPPH solution (1 mM in ethanol) with 3 ml of different concentrations 
of ropinirole (50, 40, 30, 20, 10, and 5 µg/ml) in ethanol was shaken 
and incubated in dark for 20 minutes at room temperature. Ropinirole 
was soluble in ethanol, and its various concentrations were prepared 
by dilution method. The resultant absorbance was recorded at 
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517 nm using a spectrophotometer (HACH 4000 DU ultraviolet-visible 
spectrophotometer). This procedure was similarly repeated for different 
concentrations of pramipexole (50, 40, 30, 20, 10, and 5 µg/ml), and the 
resultant absorbance was recorded at 517 nm. Ascorbic acid was used 
as the reference standard and dissolved in distilled water to make the 
stock solution with same concentration (100 µg/ml). Control sample 
was prepared containing the same volume. 95% ethanol served as 
blank. The percentage of DPPH free radical scavenging was calculated 
using the formula:
×
Ac-Asor AtScavenging %= 100
Ac
Where, Ac is absorbance of control and As or At is the absorbance 
of standard or test. The inhibitory concentration (IC50) value was 
calculated using Microsoft excels 2016. A scatter graph was made in 
excel, and the slope equation Y=a*X+b was obtained. With this equation, 
the IC50 was calculated using the formula IC50=(0.5−b)/a.
RESULTS
At concentrations of 5, 10, 20, 30, 40, and 50 µg/ml absorbance observed 
with ropinirole was 0.2256, 0.1486, 0.0869, 0.0745, 0.0629, and 0.0527, 
respectively. At the same concentrations, the absorbance observed with 
pramipexole was 0.2216, 0.1239, 0.0745, 0.0648, 0.0365, and 0.0294, 
respectively. Ascorbic acid which was the reference standard showed 
the absorbance of 0.1916, 0.1182, 0.0416, 0.0391, 0.0335, and 0.0261.
At concentrations of 5, 10, 20, 30, 40, and 50 µg/ml, the percentage of 
inhibition of DPPH free radical activity observed with ropinirole was 
7.66%, 39.22%, 64.46%, 69.54%, 74.24%, and 78.44%, respectively 
(Table 1). At the same concentrations, the percentage of inhibition 
observed with pramipexole was 9.33%, 49.32%, 69.55%, 73.49%, 
85.07%, and 88.01%, respectively (Table 1). Ascorbic acid which was 
the reference standard had the percentage of inhibition of 21.61%, 
51.66%, 83.01%, 84.02%, 86.32%, and 89.34% (Table 1). The IC50 
value calculated was 16.29, 18.19, and 10.16 µg/ml for ropinirole, 
pramipexole, and ascorbic acid, respectively (Fig. 1-3).
DISCUSSION
Studies conducted earlier by Hauser et al., Gaki and Papavassiliou, and 
Niranjan [2,14,15] have shown that increased oxidative stress and free 
radical formation contributes to the pathogenesis of Parkinson’s disease. 
Hence, drug molecules which have free radical scavenging property will 
have the neuroprotective effect in patients with Parkinson’s disease. 
From our study, the free radical scavenging property as measured by 
DPPH method showed that ropinirole and pramipexole have got an 
effective free radical scavenging activity when compared with ascorbic 
acid which was used as a standard (Fig. 4). The results of this study 
are analogous with the studies conducted earlier by Joyce et al., Park 
et al., and Tanaka et al. [16-18]. Hence, from our study and other studies 
conducted earlier, it is evident that even non-ergot derivatives such as 
pramipexole and ropinirole might have additional beneficial effects 
in the disease because of its antioxidant activity apart from acting as 
selective D2/D3 dopamine receptor agonists.
CONCLUSION
In this study, both ropinirole and pramipexole showed increasing free 
radical scavenging activity with increasing concentrations. Among the two 
drugs, pramipexole and ropinirole which were subjected to in-vitro DPPH 
Table 1: Percentage of inhibition of ropinirole, pramipexole, and ascorbic acid at various concentrations
Compound concentration (µg/ml) Ropinirole (% inhibition) Pramipexole (% inhibition) Ascorbic acid (% inhibition)
5 7.66 9.33 21.61
10 39.22 49.32 51.66
20 64.46 69.55 83.01
30 69.54 73.49 84.02
40 74.24 85.07 86.32
50 78.44 88.01 89.34
Fig. 1: Determination of inhibitory concentration 50 of ropinirole 
using linear regression
Fig. 2: Determination of inhibitory concentration 50 of 
pramipexole using linear regression
Fig. 3: Determination of inhibitory concentration 50 of ascorbic 
acid using linear regression
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Fig. 4: 1, 1-diphenyl-2picrylhydrazyl radical scavenging activity of 
ropinirole, pramipexole, and ascorbic acid
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assay, pramipexole showed the slightly higher percentage of inhibition 
when compared to ropinirole at all concentrations. However, the IC50 
levels of both the drugs were almost similar. Hence, this study shows that 
pramipexole and ropinirole have got good free radical scavenging activity 
and is non-inferior to each other and could play a role of neoadjuvant 
antioxidant in a wide variety of neurodegenerative disorders.
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